More recently, genomic profiling has identified KRAS, BRAF, and KRAS/TP53 co-mutations associating with poor prognosis (5–7); however, patient responses to treatment are unpredictable and successful development of novel therapies targeting stage IV colorectal cancer remains challenging (8). This evidence concerns the gene TP53 and colorectal cancer.